Genetic evidence for repurposing of glucagon-like peptide-1 receptor agonists to prevent chronic liver diseases

Gut. 2024 Apr 5;73(5):879-882. doi: 10.1136/gutjnl-2024-332254.

Authors

Baike Liu^#¹, Ge Peng^#², Yuan Yin¹, Chaoyong Shen¹, Xiaonan Yin¹, Zhaolun Cai¹, Bo Zhang³

Affiliations

¹ Gastric Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
² Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
³ Gastric Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China zhangbo_scu@scu.edu.cn.

^# Contributed equally.

PMID: 38490731
DOI: 10.1136/gutjnl-2024-332254

No abstract available

Keywords: DIABETES MELLITUS; HEPATOCELLULAR CARCINOMA; NONALCOHOLIC STEATOHEPATITIS.

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2*
Glucagon-Like Peptide-1 Receptor Agonists
Humans
Hypoglycemic Agents
Non-alcoholic Fatty Liver Disease*

Substances

Glucagon-Like Peptide-1 Receptor Agonists
Hypoglycemic Agents